CC
Commodore Capital Portfolio holdings
AUM
$1.42B
This Quarter Return
+37.69%
1 Year Return
+73.3%
3 Year Return
+1,330.82%
5 Year Return
–
10 Year Return
–
AUM
$251M
AUM Growth
+$251M
(+36%)
Cap. Flow
+$40.3M
Cap. Flow
% of AUM
16.05%
Top 10 Holdings %
Top 10 Hldgs %
55.61%
Holding
35
New
7
Increased
11
Reduced
7
Closed
4
Top Buys
| 1 |
STSA
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
|
$14.4M |
| 2 |
Kura Oncology
KURA
|
$11M |
| 3 |
CBAY
Cymabay Therapeutics
CBAY
|
$6.8M |
| 4 |
Dyne Therapeutics
DYN
|
$6.68M |
| 5 |
KalVista Pharmaceuticals
KALV
|
$5.51M |
Top Sells
| 1 |
Aclaris Therapeutics
ACRS
|
$7.77M |
| 2 |
FPRX
Five Prime Therapeutics, Inc.
FPRX
|
$6.43M |
| 3 |
SURF
Surface Oncology, Inc. Common Stock
SURF
|
$4.32M |
| 4 |
Immunovant
IMVT
|
$3.87M |
| 5 |
Xenon Pharmaceuticals
XENE
|
$2.97M |
Sector Composition
| 1 | Healthcare | 95.54% |
| 2 | Financials | 1.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Aclaris Therapeutics
ACRS
$209M
| $25.9M | 10.32% | 1,028,084 -308,191 | -23% | -$7.77M |
|
2
C4 Therapeutics
CCCC
$185M
| $17.8M | 7.09% | 481,094 | – | – |
|
|
3
Kura Oncology
KURA
$686M
| $14.7M | 5.87% | 521,555 +388,052 | +291% | +$11M |
|
|
STSA
4
DELISTED
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
| $14.4M | 5.72% | +2,431,705 | New | +$14.4M |
|
|
FPRX
5
DELISTED
Five Prime Therapeutics, Inc.
FPRX
| $13.6M | 5.42% | 361,344 -170,656 | -32% | -$6.43M |
|
|
CBAY
6
DELISTED
Cymabay Therapeutics
CBAY
| $13.5M | 5.4% | 2,983,513 +1,497,406 | +101% | +$6.8M |
|
7
Cogent Biosciences
COGT
$1.69B
| $11.1M | 4.44% | 1,269,195 +509,170 | +67% | +$4.47M |
|
|
ISEE
8
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $10.7M | 4.26% | 1,729,041 +454,780 | +36% | +$2.81M |
|
9
Protagonist Therapeutics
PTGX
$3.67B
| $9.06M | 3.61% | 349,600 +2,100 | +0.6% | +$54.4K |
|
|
KRON
10
DELISTED
Kronos Bio
KRON
| $8.75M | 3.48% | 298,839 | – | – |
|
|
CNST
11
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
| $8.62M | 3.43% | 368,448 -55,260 | -13% | -$1.29M |
|
|
TRIL
12
DELISTED
Trillium Therapeutics Inc.
TRIL
| $8.55M | 3.41% | 795,868 -57,003 | -7% | -$612K |
|
13
VistaGen Therapeutics
VTGN
$102M
| $7.94M | 3.16% | 3,729,694 +579,694 | +18% | +$1.23M |
|
|
GNCA
14
DELISTED
Genocea Biosciences, Inc.
GNCA
| $7.78M | 3.1% | 2,871,624 +1,105,723 | +63% | +$3M |
|
15
Celldex Therapeutics
CLDX
$1.47B
| $7.62M | 3.04% | 369,951 +13,520 | +4% | +$279K |
|
16
Mersana Therapeutics
MRSN
$36.5M
| $6.95M | 2.77% | 429,228 +270,401 | +170% | +$4.38M |
|
|
MREO
17
Mereo BioPharma
MREO
$272M
| $6.9M | 2.75% | 2,048,757 +194,479 | +10% | +$655K |
|
|
18
Dyne Therapeutics
DYN
$1.92B
| $6.68M | 2.66% | +430,112 | New | +$6.68M |
|
19
Relmada Therapeutics
RLMD
$37.2M
| $5.69M | 2.27% | 161,565 -17,000 | -10% | -$599K |
|
|
20
KalVista Pharmaceuticals
KALV
$678M
| $5.51M | 2.19% | +214,467 | New | +$5.51M |
|
|
21
Xenon Pharmaceuticals
XENE
$2.98B
| $5.4M | 2.15% | 301,392 -165,976 | -36% | -$2.97M |
|
22
Syndax Pharmaceuticals
SNDX
$1.41B
| $5.29M | 2.11% | 236,500 -93,815 | -28% | -$2.1M |
|
23
ESSA Pharma
EPIX
$11.4M
| $5.14M | 2.05% | +176,821 | New | +$5.14M |
|
24
ARS Pharmaceuticals
SPRY
$1.15B
| $4.24M | 1.69% | 97,143 | – | – |
|
25
PMV Pharmaceuticals
PMVP
$74.2M
| $4.11M | 1.64% | 125,000 | – | – |
|